Analysis of Single Product Dependency Risk for Boma Medical

Based on the general risk analysis framework for the medical device industry, the risk of Boma Medical’s high dependency on a single product can be evaluated from the following dimensions:

• If a single product contributes more than 50% of revenue, any decline in sales will have a significant impact on the company’s overall performance
• Risk resistance capacity is significantly reduced; performance fluctuates sharply when market volatility or competition intensifies

• After patent expiration, it may face impact from generic drugs or competing products
• Technological iteration may render the product obsolete
• Policy changes (such as medical insurance cost control, adjustment of bidding rules) may directly affect product sales

• If a single product fails to pass the registration renewal review, it will directly interrupt the revenue source
• Product adverse events may lead to recall or even delisting risks

• If the product has high technical barriers or patent protection, it can delay competitive impact
• Leading position in a niche segment may provide certain protection

• The reserve status of the pipeline of products under development determines the degree of risk mitigation
• R&D investment intensity affects the progress of product diversification

• The market size of the target disease determines the growth ceiling
• The room for penetration rate improvement affects short-to-medium-term growth potential

Referring to medical device industry practices, a single product accounting for over 70% is usually regarded as a high-risk range [1]. Mature medical device enterprises usually pursue product portfolio diversification to spread risks.

---

For a specific risk assessment of Boma Medical, it is recommended to refer to the product revenue structure disclosure section in its prospectus or annual report to obtain accurate data to support the analysis.